Literature DB >> 21143495

Editors' pick 2010.

Yoon K Loke1, Albert Ferro, Lionel D Lewis, Adam F Cohen, Andrew Somogyi, James M Ritter.   

Abstract

Mesh：

Year:  2011        PMID： 21143495      PMCID： PMC3018020          DOI： 10.1111/j.1365-2125.2010.03862.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  24 in total

Review 1.  The application of mass-spectrometry-based protein biomarker discovery to theragnostics.

Authors:  Jonathan M Street; James W Dear
Journal:  Br J Clin Pharmacol       Date:  2010-04       Impact factor: 4.335

2.  Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction.

Authors:  Zhong-Ze Fang; Yan-Yan Zhang; Guang-Bo Ge; Hong Huo; Si-Cheng Liang; Ling Yang
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

3.  Informed consent document improvement does not increase patients' comprehension in biomedical research.

Authors:  Adeline Paris; Christian Brandt; Catherine Cornu; Patrick Maison; Claire Thalamas; Jean-Luc Cracowski
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

4.  Multivariate evaluation of pharmacological responses in early clinical trials - a study of rIL-21 in the treatment of patients with metastatic melanoma.

Authors:  Morten Arendt Rasmussen; Morten Colding-Jørgensen; Lasse Tengbjerg Hansen; Rasmus Bro
Journal:  Br J Clin Pharmacol       Date:  2010-04       Impact factor: 4.335

5.  Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers.

Authors:  Jorg Taubel; Asif Naseem; Tomohiko Harada; Duolao Wang; Radivoj Arezina; Ulrike Lorch; A John Camm
Journal:  Br J Clin Pharmacol       Date:  2010-04       Impact factor: 4.335

6.  No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.

Authors:  Ester Donado; Iñaki Izquierdo; Iñaki Pérez; Olga García; Rosa M Antonijoan; Ignaci Gich; Anna Solans; Juana Peña; Joel Morganroth; Manuel J Barbanoj
Journal:  Br J Clin Pharmacol       Date:  2010-04       Impact factor: 4.335

7.  Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.

Authors:  Philipp Kiewe; Stephan Hasmüller; Steffen Kahlert; Maja Heinrigs; Brigitte Rack; Alexander Marmé; Agnieszka Korfel; Michael Jäger; Horst Lindhofer; Harald Sommer; Eckhard Thiel; Michael Untch
Journal:  Clin Cancer Res       Date:  2006-05-15       Impact factor: 12.531

8.  Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.

Authors:  Martin Sebastian; Philipp Kiewe; Wolfgang Schuette; Daniel Brust; Christian Peschel; Folker Schneller; Karl-Heinz Rühle; Georg Nilius; Ralf Ewert; Sven Lodziewski; Bernward Passlick; Wulf Sienel; Rainer Wiewrodt; Michael Jäger; Horst Lindhofer; Hilke Friccius-Quecke; Alexander Schmittel
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

9.  Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients.

Authors:  Peter Ruf; Michael Kluge; Michael Jäger; Alexander Burges; Constantin Volovat; Markus Maria Heiss; Jürgen Hess; Pauline Wimberger; Birgit Brandt; Horst Lindhofer
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

Review 10.  The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?

Authors:  Barrett W Newsome; Marc S Ernstoff
Journal:  Br J Clin Pharmacol       Date:  2008-05-22       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.